Étude de la stabilité du peptide natriurétique de type B (BNP) dans le sang total et le plasma
Immuno-analyse & Biologie Spécialisée (Impact Factor: 0.05). 07/2000; 15(4):267-272. DOI: 10.1016/S0923-2532(00)80026-5
Evaluation of BNP stability in whole blood and plasma.BNP is proposed as a biochemical marker which could provide a useful screening test to select patients for further cardiac investigations in heart failure. The applicability of such a biochemical test in clinics, hospital wards, and clinical service laboratories is dependent on its ease of use and, whether, careful and complex sample handling are necessary. The present study was undertaken to evaluate the stability of BNP under a number of different handling conditions (samples collection, storage temperatures, freezing temperatures) assayed with a commercially available kit. The results clearly demonstrate that BNP is stable at room temperature for 24 hours, or up to 30 °C for 12 h in the presence or not of aprotinin, on the condition that BNP is assayed within one month (frozen at −20 °C) after blood collection. In contrast, the presence of aprotinin prevents BNP degradation in case of preservation of samples over than one month at −20 °C before assay.
- [Show abstract] [Hide abstract]
ABSTRACT: Diagnostic value in the cardiology department of rapid whole blood B-type natriuretic peptide (BNP) testing.BNP, or B-Type natriuretic peptide, is a “cardiac hormone” released into the blood in response to left ventricular stretch. Its concentration increases with heart failure severity. A new quantitative rapid test, which may be used in an emergency setting, delivers results within 15 minutes using whole blood samples. We have used it to determine its diagnostic value in a population of patients admitted to the hospital in the cardiology department. It has allowed us to rule-out or confirm heart failure for 56 patients presenting with acute dyspnea and therefore to avoid more expensive cardiological investigations. BNP is systematically increased (mean of 1,648 pg/mL) for patients presenting with a typical clinical picture of heart failure. The level is proportional to the severity of the cardiopathy as determined by left ventricular ejection fraction. Inversely, a normal BNP level allows to rule-out heart failure. Patients with chronic cardiopathy have moderately elevated BNP levels (223 pg/mL). Knowing the level of BNP during the stability phase of chronically ill heart failure patients can be of significant help in linking the symptoms to a new decompensation event when a patient is readmitted. Levels of BNP have also been measured in patients with acute coronary syndrome. However the values where too heterogenic to be able to draw any conclusions and warrant further studies.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.